CEPI Boosts ‘Coronavirus X’ Vaccine Search with Expanded VBI Vaccines Deal
The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future ‘Coronavirus X’.
Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim
Cambridge, MA – November 29, 2022 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the acquisition of its CD38 program with Boehringer Ingelheim. This includes a small molecule inhibitor designed to modulate intra- and extracellular CD38 activity, potentially restoring immune function in various diseases, as well as corresponding patents and other proprietary information. Boehringer Ingelheim aims to develop novel therapies based on Ribon’s CD38 program to transform the lives of patients with immunological and fibrotic diseases.
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today provided a corporate update and reported financial results for the third quarter of 2022.
Inari Raises $124 Million to Design Seeds for a More Sustainable Food System
CAMBRIDGE, Mass., October 4, 2022 — Inari today announced that it secured $124 million in the successful completion of its latest fundraise. Working to deliver nature-positive solutions, the SEEDesign™ company’s cumulative equity raised now totals $475 million. The investment will further advance Inari’s leading position in multiplex gene-edited seed technology, support expansion of company product development and ultimately deliver new value in the commercial seed market.
InterWell Health, Cricket Health, and Fresenius Health Partners Complete Three-Way Merger, Creating Premier, Value-based Kidney Care Provider
CAMBRIDGE, Mass., Aug. 24, 2022 /PRNewswire/ -- InterWell Health today announced it has completed a three-way merger between Fresenius Medical Care's value-based care division, Fresenius Health Partners; InterWell Health, a leading physician organization driving innovation in the kidney care industry; and Cricket Health, a provider of value-based kidney care with an industry-leading patient engagement and data platform. The new independent company, which will operate under the InterWell Health brand, will set the standard in value-based kidney care by partnering with a patient's nephrologist, improving their care delivery throughout the entire spectrum of their journey with kidney disease. With extraordinary capabilities, expertise, and reach, the new company expects to improve health outcomes for individuals with kidney disease and reduce costs to public and private payers, health systems, and all others that take risk for this vulnerable and complex patient population. The transaction has satisfied customary closing conditions and received regulatory clearance in the U.S.